The Moorfields DMO Dataset encompasses all patients who have received at least one injection of either Lucentis (ranibizumab) or Eylea (aflibercept) to treat diabetic macular oedema (DMO) at Moorfield
Maximum Intensities Summary (Median [Minimum Value–Maximum Value]) within each Slice and the Average of the Four Slices for the Control Group (0.00) and each Lens Opacity Classification System (LOCS)
